SOUTH SAN FRANCISCO, Calif., June 23, 2025 - CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) announced the completion of the initial evaluation of the first patient in its Phase 1 clinical trial of its lead compound, CER-1236. The trial, titled "Phase 1/1b First-in-human Study of Autologous Chimeric Engulfment Receptor T-Cell CER-1236 in Patients With Acute Myeloid Leukemia (CertainT-1)," is designed to assess the safety and preliminary efficacy of CER-1236 in patients with acute myeloid leukemia. Preliminary results from the trial's Dose Escalation Safety Committee indicate that the first patient demonstrated no dose-limiting toxicity during the 28-day observation period. The company plans to dose a second patient in the cohort shortly. CERo has announced plans to initiate a second trial of CER-1236 in solid tumors later this year. Further updates on the trial's progress will be provided in the future.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.